Agreed, and I think a the discounted cash flow valuation method is more appropriate here because they will invest their postive cashflows to continue their growth trajectory without the need to raise capital. There is a compounding relationship between their revenue growth and their NPAT. Mainly driven by such a strong gross margin of over 60%. Otherwise, every dollar of revenue growth contributes $0.60 in extra cash towards a cost base that isn't growing materially.
Agreed, and I think a the discounted cash flow valuation method...
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
0.035(5.19%) |
Mkt cap ! $152.9M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 74.0¢ | 68.5¢ | $538.4K | 746.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 70.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 05/09/2024 (20 minute delay) ? |
| BIO (ASX) Chart |